The prenylation inhibitor, lonafarnib: A new therapeutic strategy against hepatitis delta

The Lancet Infectious Diseases

Volumn 15, Issue 10, 2015, Pages 1119-1120

  Rizzetto, Mario ^a   Ciancio, Alessia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LONAFARNIB; ANTIVIRUS AGENT; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL PRACTICE; DELTA AGENT HEPATITIS; DOSE RESPONSE; HEPATITIS DELTA VIRUS; HUMAN; NONHUMAN; NOTE; POPULATION RESEARCH; PRIORITY JOURNAL; VIRUS MUTATION; FEMALE; HEPATITIS D, CHRONIC; MALE;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS D, CHRONIC; HUMANS; MALE; PIPERIDINES; PYRIDINES;

EID: 84942191298     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00155-3     Document Type: Note

References (13)

1. Rizzetto M Hepatitis D: thirty years after. J Hepatol 2009, 50:1043-1050.
2. Taylor JM Structure and replication of hepatitis delta virus RNA. Curr Top Microbiol Immunol 2006, 307:1-23.
3. Rizzetto M, Ciancio A Epidemiology of hepatitis D. Semin Liver Dis 2012, 32:211-219.
4. Ciancio A, Rizzetto M Chronic hepatitis D at a standstill: where do we go from here?. Nat Rev Gastroenterol Hepatol 2014, 11:68-71.
5. Taylor JM Chapter 3. Replication of the hepatitis delta virus RNA genome. Adv Virus Res 2009, 74:103-121.
6. Yurdaydin C Treatment of chronic delta hepatitis. Semin Liver Dis 2012, 32:237-244.
7. Huang WH, Chen CW, Wu HL, Chen PJ Post-translational modification of delta antigen of hepatitis D virus. Curr Top Microbiol Immunol 2006, 307:91-112.
8. Glenn JS, Watson JA, Havel CM, White JM Identification of a prenylation site in delta virus large antigen. Science 1992, 256:1331-1333.
9. Glenn JS, Marsters JC, Greenberg HB Use of a prenylation inhibitor as a novel antiviral agent. J Virol 1998, 72:9303-9306.
10. Koh C, Canini L, Dahari H, et al. OOral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis 2015, published online July 17. http://dx.doi.org/10.1016/S1473-3099(15)00074-2.
11. Ciancio A, Rizzetto M PEG-IFN for the treatment of hepatitis D. Nat Rev Gastroenterol Hepatol 2011, 8:304-306.
12. Urban S, Bartenschlager R, Kubitz R, Zoulim F Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 2014, 147:48-64.
13. Bazinet M, Pantea V, Cebotarescu V, et al. Significant reduction of HBsAg and HDV-RNA by the nucleic acid polymer REP-2139 in Caucasian patients with chronic HBV/HDV co-infection. J Hepatol 2015, 62:257.